Vioxx (rofecoxib) belongs to a class of cyclo-oxygenase 2 (COX-2) inhibitor selective non-steroidal anti-inflammatory drugs (NSAIDs), which are prescribed for the treatment of arthritis. Vioxx was withdrawn from the pharmaceutical market at the end of September 2004 after use of the drug was linked to heart problems.
David J Graham (Office of Drug Safety, US Food and Drug Administration) and colleagues assessed whether coronary heart disease risk was increased with either high or standard doses of Vioxx compared with other (NSAIDs) or the COX-2 inhibitor celecoxib (Celebrex), a drug commonly used as an alternative to Vioxx.
They analysed data from 1.4 million people in California who had used NSAIDs from the beginning of 1999 to September 2004. Patients had received various NSAIDs, including celecoxib (around 40,000 users), ibuprofen (just under a million users), naproxen (around 435,000 users), and rofecoxib (around 27,000 users). The investigators found that 8,143 individuals had serious coronary heart disease, 1508 of which had sudden cardiac death. Each case was matched by age and sex to four controls to enable a comparison of coronary heart disease risk among people taking Vioxx and users of other NSAIDs.
People taking Vioxx had a 34% higher chance of coronary heart disease when compared with people who used other NSAIDs. Coronary heart disease was 1.6 times more likely among people currently taking standard-dose Vioxx compared with those currently taking celecoxib and 3.6 times more likely among high-dose users. The study also found that people taking naproxen had a 14% increased risk of coronary heart disease compared with other NSAIDs. Previous studies have suggested that naproxen protects against coronary hear
Contact: Joe Santangelo